甲亢所致重度黄疸在甲亢性肝损伤中少见且危重，临床治疗棘手。本例患者为23岁男性，1年半前确诊甲亢，口服抗甲状腺药物后出现肝损伤，停药保肝治疗后肝功能恢复正常。予甲状腺局部注射环磷酰胺+地塞米松治疗8个月后甲亢好转，未继续治疗。4个月前甲亢复发，肝功能再次出现异常，予多种保肝药物及静脉应用糖皮质激素，胆红素仍持续进行性升高。入院后明确为甲亢所致肝损伤，但患者存在重度黄疸，手术及131I治疗甲亢均存在较大风险，故在稳定心率、保肝退黄及小剂量糖皮质激素治疗基础上利用人工肝支持系统进行治疗。治疗后，黄疸及高代谢症状均较前明显减轻，血胆红素、甲状腺素、甲状腺自身抗体水平明显降低。之后予131I治疗，目前肝功能已恢复正常，甲亢明显改善。
Abstract
Severe jaundice is a rare and severe liver injury caused by hyperthyroidism, which is troublesome in clinical practice.A 23-year-old male was admitted with hyperthyroidism and severe jaundice.One and a half years ago, he got liver damage after oral antithyroid drugs,liver function returned to normal via antithyroid drugs withdrawal and liver protection treatment.Then he accepted injection of cyclophosphamide and dexamethasone in thyroid gland for 8 months,and discontinued when the serum thyroxine returned to normal.However,hyperthyroidism recurred 4 months ago,and abnormal liver function appeared again. His serum bilirubin kept rising in spite of various liver protection drugs and intravenous glucocorticoids treatment.After admission, hyperthyroidism was confirmed as the cause of liver injury.However,in the case of severe jaundice, both surgery and 131I treatment for hyperthyroidism are of high risk.Therefore,based on the treatment of heart rate control,liver protection and low-dose glucocorticoid,artificial liver support system was added, then his jaundice and hypermetabolism symptoms were both relieved,serum bilirubin,thyroxine,thyroid autoantibody levels were significantly reduced.Thereafter,he accepted 131I treatment,and then hyperthyroidism has been significantly relieved and the liver function has returned to normal range.
关键词
Grave's病 /
重度黄疸 /
人工肝支持系统
{{custom_keyword}} /
Key words
Grave's disease /
severe jaundice /
artificial liver support system
{{custom_keyword}} /
中图分类号：
R581.1
R575.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SCAPPATICCIO L,LONGO M,MAIORINO MI,et al. Abnormal liver blood tests in patients with hyperthyroidism:systematic review and meta-analysis[J/OL].Thyroid,online ahead of print[2021-01-21].https://doi.org/10.1089/thy.2020.0715.
[2] LIN TY,SHEKAR AO,LI N,et al.Incidence of abnormal liver biochemical tests in hyperthyroidism[J].Clin Endocrinol (Oxf),2017,86(5),755-759.
[3] TANAKA A.Autoimmune hepatitis:2019 update[J].Gut Liver,2020,14(4):430-438.
[4] OKWARA CJ,MOJTAHED A,GAVIN M,et al.Jaundice:a thyroid problem?[J].Dig Dis Sci,2017,62(8):1901-1905.
[5] WICKRAMASINGHE RD,LUKE WA,SEBASTIAMPILLAI BS,et al.Thyrotoxic crisis presenting with jaundice[J].BMC Res Notes,2016,9:320.
[6] BHUYAN AK,SARMA D,KAIMAL SAIKIA U,et al.Graves' disease with severe hepatic dysfunction:a diagnostic and therapeutic challenge[J].Case Rep Med,2014,2014:790458.
[7] SUBEKTI I,PRAMONO LA.Current diagnosis and management of Graves' disease[J].Acta Med Indones,2018,50(2):177-182.
[8] JAGER B,DROLZ A,MICHL B,et al.Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis[J].Hepatology,2012,56(6):2297-2304.
[9] 中华医学会感染病学分会肝衰竭与人工肝学组.非生物型人工肝治疗肝衰竭指南(2016年版)[J].中华临床感染病杂志,2016,9(2):97-103.
[10] TANDON R,FROGHI S.Artificial liver support systems[J/OL].J Gastroenterol Hepatol,online ahead of print[2020-09-12].https://doi.org/10.1111/jgh.15255.
[11] SHEN Y,WANG XL,WANG B,et al.Survival benefits with artificial liver support system for acute-on-chronic liver failure:a time series-based meta-analysis[J].Medicine (Baltimore),2016,95(3):e2506.
[12] DROLZ A,SAXA R,SCHERZER T,et al.Extracorporeal artificial liver support in hypoxic liver injury[J].Liver Int,2011,31(Suppl 3):19-23.
[13] 张庆,张伦理,向天新,等.人工肝系统联合131I治疗甲状腺功能亢进症合并肝衰竭研究[J].中华肝脏病杂志,2016,24(10):778-782.
[14] TAN YW,SUN L,ZHANG K,et al.Therapeutic plasma exchange and a double plasma molecular absorption system in the treatment of thyroid storm with severe liver injury:a case report[J].World J Clin Cases,2019,7(10):1184-1190.
[15] 骆磊,朱郧鹤,杜兴邦,等.131I联合人工肝血浆置换治疗Graves甲亢合并中-重度肝损害156例疗效分析[J].标记免疫分析与临床,2019,26(6):963-966.
[16] 胡晖,张阳德,邓豪余,等.131I结合人工肝支持系统治疗甲亢合并重型肝炎[J].中华核医学杂志,2006,26(2):115-117.
[17] 张成席,胡继清,何雨洁.131I联合ALSS治疗甲亢合并重型肝炎疗效分析[J].当代医学,2013(4):13-14.
[18] 张青,张庆,张伦理,等.131Ⅰ联合分子吸附再循环系统人工肝治疗Graves甲亢并重度肝脏损害[J].南昌大学学报(医学版),2012,52(2):23-26.
[19] 杨丽霞,李小鹏,张伦理.人工肝结合131I治疗与内科常规治疗40例甲亢合并重症肝损害疗效的比较[J].世界华人消化杂志,2011,19(28):2983-2986.
[20] THOMAS H,ANDREAS D,MICHAEL T,et al.Liver injury and failure in critical illness[J].Hepatology,2019,70(6):2204-2215.
[21] 范文瀚,罗怡平,李成忠.糖皮质激素应用于肝衰竭治疗机制及其临床时机的把握[J].实用肝脏病杂志,2020,23(1):7-9.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金（81770802）
{{custom_fund}}
PDF(7762 KB)
